EP2852574B1 - Verfahren für sorafenib-tosylatpolymorph iii - Google Patents

Verfahren für sorafenib-tosylatpolymorph iii Download PDF

Info

Publication number
EP2852574B1
EP2852574B1 EP13793172.1A EP13793172A EP2852574B1 EP 2852574 B1 EP2852574 B1 EP 2852574B1 EP 13793172 A EP13793172 A EP 13793172A EP 2852574 B1 EP2852574 B1 EP 2852574B1
Authority
EP
European Patent Office
Prior art keywords
sorafenib tosylate
sorafenib
polymorph iii
alcoholic solvent
mixture
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
EP13793172.1A
Other languages
English (en)
French (fr)
Other versions
EP2852574A4 (de
EP2852574A2 (de
Inventor
Bandi Parthasaradhi Reddy
Kura Rathnakar Reddy
Dasari Muralidhara Reddy
Thungathurthy Srinivasa Rao
Bandi Vamsi Krishna
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Hetero Research Foundation
Original Assignee
Hetero Research Foundation
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Hetero Research Foundation filed Critical Hetero Research Foundation
Publication of EP2852574A2 publication Critical patent/EP2852574A2/de
Publication of EP2852574A4 publication Critical patent/EP2852574A4/de
Application granted granted Critical
Publication of EP2852574B1 publication Critical patent/EP2852574B1/de
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D213/78—Carbon atoms having three bonds to hetero atoms, with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C07D213/81—Amides; Imides

Definitions

  • the present invention provides a novel process for the preparation of sorafenib tosylate polymorph III.
  • Sorafenib chemically 4- ⁇ 4-[( ⁇ [4-chloro-3-(trifluoromethyl)phenyl]amino ⁇ -carbonyl)amino]phenoxy ⁇ -N-methyl-2-pyridinecarboxamide and has the structural formula:
  • Sorafenib tosylate is a well-known antineoplastic agent, and was useful for the treatment of primary kidney cancer (advanced renal cell carcinoma) and advanced primary liver cancer (hepatocellular carcinoma).
  • the generic name sorafenib tosylate is marketed by Bayer Healthcare under the brand name NEXAVAR®.
  • Sorafenib was disclosed in International application publication no. WO 2000/042012 .
  • Sorafenib tosylate was disclosed in International application publication nos. WO 2003/068228 and WO 2003/047579 .
  • sorafenib tosylate polymorph III can be prepared by suspending sorafenib tosylate in methanol at room temperature, maintained for one week and then filtered to obtain a residual solid. The residual solid was heat-treated at 150°C for 30 minutes to obtain sorafenib tosylate polymorph III.
  • sorafenib tosylate polymorph III can be prepared by providing a suspension comprising sorafenib tosylate and a solvent selected from methanol, a mixture of methanol and N-methyl-2-pyrrolidone, a mixture of methanol and dimethyl sulfoxide to obtain sorafenib tosylate methanol solvate and then drying the sorafenib tosylate methanol solvate at 80 to 90°C.
  • an object of the present invention is to provide a novel process for the preparation of sorafenib tosylate polymorph III.
  • Figure 1 is a powder X-ray diffractogram patterns of sorafenib tosylate polymorph III.
  • Powder X-ray diffraction spectrum was measured on a bruker AXS D8 advance powder X-ray diffractometer having a copper-Ka radiation. Approximately 500 mg of sample was gently flattered on a sample holder and scanned from 2 to 50 degrees two-theta, at 0.020 degrees two theta per step and a step time of 1 second. The sample was simply placed on the sample holder. The sample was rotated at 30 rpm at a voltage 40 kV and current 35 mA.
  • room temperature refers to temperature at about 25 to 35°C.
  • the present invention provides a process for the preparation of sorafenib tosylate polymorph III characterized by powder X-ray diffractogram as shown in Figure 1 , which comprises:
  • Isolation of the solid in step (c) may preferably be performed by conventional techniques such as centrifugation or filtration.
  • step (d) The temperature at which slurrying in step (d) is carried out is not critical and the slurrying may conveniently be carried out at room temperature.
  • Chloro tri-fluoro aniline 72 gm was dissolved in methylene chloride (600 ml) and then added carbonyldiimidazole (64 gm) at room temperature. The reaction mixture was maintained for 18 hours at room temperature and then added 4-(2-(N-methylcarbamoyl)-4-pyridyloxy)aniline (85 gm) in methylene chloride (850 ml) slowly for 45 minutes. The reaction mass was maintained for 48 hours at room temperature and filtered. The solid obtained was dried at 40 to 45°C under vacuum for 2 hours to obtain 90 gm of sorafenib.
  • sorafenib 50 gm as obtained in example 1, p-toluenesulfonic acid (29 gm), dimethyl acetamide (100 ml) and methanol (65 ml) were stirred for 20 minutes at room temperature.
  • methanol 800 ml
  • methanol 750 ml
  • the separated solid was filtered and then dried at 65 to 70°C for 11 hours to obtain 50 gm of sorafenib tosylate polymorph III.

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Pyridine Compounds (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)

Claims (1)

  1. Verfahren zur Herstellung von Sorafenib Tosylat Polymorph III, gekennzeichnet durch ein Pulverröntgendiffraktogramm wie in Abbildung 1 gezeigt, welches umfasst:
    a. Bereitstellen einer Lösung umfassend Sorafenib, p-Toluolsulfonsäure und ein Lösemittel, welches aus der Gruppe bestehend aus einem Gemisch von Dimethylacetamid und einem Alkohollösemittel, einem Gemisch von Dimethylfomamid und einem Alkohollösemittel und einem Gemisch davon ausgewählt wird.
    b. Zufügen eines Alkohollösemittels zur Lösung, die durch Schritt (a) erhalten wurde.
    c. Isolieren des Feststoffs
    d. Aufschlämmen des Feststoffs aus Schritt (c) in einem Alkohollösemittel; und
    e. Isolieren von Sorafenib Tosylat Polymorph III durch Filtrieren und anschließendes Trocknen bei 65 bis 70°C für 11 Stunden;
    wobei das in Schritt (a), (b) und (d) verwendete Alkohollösemittel Methanol ist.
EP13793172.1A 2012-05-21 2013-05-21 Verfahren für sorafenib-tosylatpolymorph iii Active EP2852574B1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
IN1995CH2012 2012-05-21
PCT/IN2013/000325 WO2013175506A2 (en) 2012-05-21 2013-05-21 Process for sorafenib tosylate polymorph iii

Publications (3)

Publication Number Publication Date
EP2852574A2 EP2852574A2 (de) 2015-04-01
EP2852574A4 EP2852574A4 (de) 2015-10-28
EP2852574B1 true EP2852574B1 (de) 2020-02-05

Family

ID=49624460

Family Applications (1)

Application Number Title Priority Date Filing Date
EP13793172.1A Active EP2852574B1 (de) 2012-05-21 2013-05-21 Verfahren für sorafenib-tosylatpolymorph iii

Country Status (3)

Country Link
US (1) US9156789B2 (de)
EP (1) EP2852574B1 (de)
WO (1) WO2013175506A2 (de)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN104761492A (zh) * 2014-01-03 2015-07-08 正大天晴药业集团股份有限公司 对甲苯磺酸索拉非尼的晶型及其制备方法
CN104402813B (zh) * 2014-12-15 2017-05-10 哈药集团制药总厂 一种索拉非尼的制备方法
EP3109236B1 (de) 2015-06-23 2017-08-09 F.I.S.- Fabbrica Italiana Sintetici S.p.A. Skalierbares verfahren zur herstellung von sorafenib-tosylat-ethanolsolvat und sorafenib-tosylatform iii
CN107840823B (zh) * 2016-09-20 2021-08-17 意大利合成制造有限公司 用于制备甲苯磺酸索拉非尼乙醇溶剂化物和iii型甲苯磺酸索拉非尼的可变规模的方法
CN108164459B (zh) * 2016-12-07 2021-07-27 上海创诺制药有限公司 甲苯磺酸索拉非尼晶型iii的制备方法
CN109422676A (zh) * 2017-09-01 2019-03-05 广州白云山医药集团股份有限公司白云山制药总厂 索拉非尼晶型及其制备方法
CN109796400B (zh) * 2017-11-16 2022-07-29 四川科伦药物研究院有限公司 一种甲苯磺酸索拉菲尼晶型及其制备方法
CN111704574B (zh) * 2019-03-17 2024-05-07 齐鲁制药有限公司 一种高纯度甲苯磺酸索拉非尼晶型iii的制备方法

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1140840B1 (de) 1999-01-13 2006-03-22 Bayer Pharmaceuticals Corp. -g(v)-carboxyaryl substituierte diphenyl harnstoffe als raf kinase inhibitoren
ES2275931T5 (es) 2001-12-03 2018-10-23 Bayer Healthcare Llc Compuestos de aril-urea en combinación con otros agentes citostáticos o citotóxicos para tratamiento de cánceres humanos
DK1478358T3 (da) 2002-02-11 2013-10-07 Bayer Healthcare Llc Sorafenibtosylat til behandling af sygdomme kendetegnet ved unormal angiogenese
BRPI0515946A (pt) 2004-09-29 2008-08-12 Bayer Healthcare Ag sal de tosilato, sua preparação e uso, bem como composição farmacêutica compreendendo o mesmo
US8217061B2 (en) * 2008-01-17 2012-07-10 Sicor Inc. Polymorphs of sorafenib tosylate and sorafenib hemi-tosylate, and processes for preparation thereof
WO2010142678A2 (en) 2009-06-12 2010-12-16 Ratiopharm Gmbh Polymorphs of 4-[4-[[4-chloro-3-(trifluoromethyl)phenyl]carbamoylamino]phenoxy]-n-methyl-pyridine-2-carboxamide
CA2788146C (en) 2010-01-29 2014-11-25 Ranbaxy Laboratories Limited Sorafenib dimethtyl sulphoxide solvate

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
None *

Also Published As

Publication number Publication date
EP2852574A4 (de) 2015-10-28
WO2013175506A2 (en) 2013-11-28
US9156789B2 (en) 2015-10-13
EP2852574A2 (de) 2015-04-01
WO2013175506A3 (en) 2014-06-26
US20150133670A1 (en) 2015-05-14

Similar Documents

Publication Publication Date Title
EP2852574B1 (de) Verfahren für sorafenib-tosylatpolymorph iii
US8217061B2 (en) Polymorphs of sorafenib tosylate and sorafenib hemi-tosylate, and processes for preparation thereof
EP2878598B1 (de) Kristalline form von 4-[5-pyridin-4-yl]-1h-1,2,4-triazol-3-yl]pyridin-2-carbonitril
US8703788B2 (en) Polymorph of nilotinib hydrochloride
CA2775229C (en) Process for the preparation of sorafenib tosylate
WO2014086326A1 (en) A method for the preparation and purification of new and known polymorphs and solvates of dasatinib
US8598341B2 (en) Process for etravirine intermediate and polymorphs of etravirine
US7456181B2 (en) Aripiprazole crystalline forms
TW201617336A (zh) 鉀離子競爭性酸阻滯劑的晶型及其製備方法
EP2688649B1 (de) Ein polymorph von lenalidomid
WO2011061611A1 (en) Process for the preparation of form b of lenalidomide
WO2012004801A1 (en) Process for imatinib mesylate
EP2142507A1 (de) Verfahren zur herstellung von sorafenib und salzen daraus
WO2012071425A1 (en) Solid state forms of sorafenib besylate, and processes for preparations thereof
WO2012168948A2 (en) Process for febuxostat
WO2014195977A2 (en) Novel polymorphs of vismodegib
JP5827684B2 (ja) ２−［３−シアノ−４−（２−ｉ−ブトキシ）フェニル］−４−メチル−５−チアゾール−カルボン酸（フェブキソスタット）の結晶形Ａを調製するための方法
US20180273490A1 (en) Process for the Preparation of Eltrombopag Olamine
US20130190368A1 (en) Novel polymorphs of febuxostat
CA2892919A1 (en) Process for making reverse transcriptase inhibitors
US10206874B2 (en) Rufinamide solid dispersion
WO2010079498A2 (en) Novel polymorph of sorafenib tosylate
WO2010079497A2 (en) Novel polymorph of atazanavir sulfate
JP2014031360A (ja) 無水アリピプラゾール結晶及びその製造方法
CN110423215B (zh) 一种查尔酮吡啶盐及其制备方法和应用

Legal Events

Date Code Title Description
PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

17P Request for examination filed

Effective date: 20141209

AK Designated contracting states

Kind code of ref document: A2

Designated state(s): AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR

AX Request for extension of the european patent

Extension state: BA ME

RAP1 Party data changed (applicant data changed or rights of an application transferred)

Owner name: HETERO RESEARCH FOUNDATION

DAX Request for extension of the european patent (deleted)
A4 Supplementary search report drawn up and despatched

Effective date: 20150930

RIC1 Information provided on ipc code assigned before grant

Ipc: C07D 213/81 20060101AFI20150924BHEP

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: EXAMINATION IS IN PROGRESS

17Q First examination report despatched

Effective date: 20180927

GRAP Despatch of communication of intention to grant a patent

Free format text: ORIGINAL CODE: EPIDOSNIGR1

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: GRANT OF PATENT IS INTENDED

INTG Intention to grant announced

Effective date: 20190822

GRAS Grant fee paid

Free format text: ORIGINAL CODE: EPIDOSNIGR3

GRAA (expected) grant

Free format text: ORIGINAL CODE: 0009210

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE PATENT HAS BEEN GRANTED

RAP1 Party data changed (applicant data changed or rights of an application transferred)

Owner name: HETERO RESEARCH FOUNDATION

RIN1 Information on inventor provided before grant (corrected)

Inventor name: MURALIDHARA REDDY, DASARI

Inventor name: VAMSI KRISHNA, BANDI

Inventor name: RATHNAKAR REDDY, KURA

Inventor name: PARTHASARADHI REDDY, BANDI

Inventor name: SRINIVASA RAO, THUNGATHURTHY

AK Designated contracting states

Kind code of ref document: B1

Designated state(s): AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR

REG Reference to a national code

Ref country code: GB

Ref legal event code: FG4D

REG Reference to a national code

Ref country code: AT

Ref legal event code: REF

Ref document number: 1229803

Country of ref document: AT

Kind code of ref document: T

Effective date: 20200215

REG Reference to a national code

Ref country code: DE

Ref legal event code: R096

Ref document number: 602013065502

Country of ref document: DE

REG Reference to a national code

Ref country code: IE

Ref legal event code: FG4D

REG Reference to a national code

Ref country code: CH

Ref legal event code: EP

REG Reference to a national code

Ref country code: NL

Ref legal event code: MP

Effective date: 20200205

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: PT

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20200628

Ref country code: NO

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20200505

Ref country code: FI

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20200205

Ref country code: RS

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20200205

REG Reference to a national code

Ref country code: LT

Ref legal event code: MG4D

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: IS

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20200605

Ref country code: SE

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20200205

Ref country code: LV

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20200205

Ref country code: GR

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20200506

Ref country code: HR

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20200205

Ref country code: BG

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20200505

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: NL

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20200205

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: EE

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20200205

Ref country code: SM

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20200205

Ref country code: RO

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20200205

Ref country code: CZ

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20200205

Ref country code: ES

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20200205

Ref country code: LT

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20200205

Ref country code: SK

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20200205

Ref country code: DK

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20200205

REG Reference to a national code

Ref country code: DE

Ref legal event code: R097

Ref document number: 602013065502

Country of ref document: DE

REG Reference to a national code

Ref country code: AT

Ref legal event code: MK05

Ref document number: 1229803

Country of ref document: AT

Kind code of ref document: T

Effective date: 20200205

REG Reference to a national code

Ref country code: DE

Ref legal event code: R119

Ref document number: 602013065502

Country of ref document: DE

PLBE No opposition filed within time limit

Free format text: ORIGINAL CODE: 0009261

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: NO OPPOSITION FILED WITHIN TIME LIMIT

26N No opposition filed

Effective date: 20201106

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: MC

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20200205

Ref country code: CH

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20200531

Ref country code: LI

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20200531

Ref country code: AT

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20200205

Ref country code: IT

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20200205

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: SI

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20200205

Ref country code: PL

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20200205

REG Reference to a national code

Ref country code: BE

Ref legal event code: MM

Effective date: 20200531

GBPC Gb: european patent ceased through non-payment of renewal fee

Effective date: 20200521

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: LU

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20200521

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: FR

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20200531

Ref country code: GB

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20200521

Ref country code: IE

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20200521

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: BE

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20200531

Ref country code: DE

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20201201

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: TR

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20200205

Ref country code: MT

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20200205

Ref country code: CY

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20200205

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: MK

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20200205

Ref country code: AL

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20200205